- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07948967
Physiological Associations and Prognostic Discrimination of an EIT-Derived Flow Index During Noninvasive Ventilation (NIV-EFI)
Physiological Associations and Prognostic Discrimination of an Electrical Impedance Tomography-Derived Flow Index During Noninvasive Ventilation: A Multicenter Prospective Cohort With a Nested Physiological Substudy
This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.
Panoramica dello studio
Stato
Descrizione dettagliata
This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.
A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and |Pocc|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Rui Zhang
- Numero di telefono: +86-18801119381
- Email: ccmzhangrui@foxmail.com
Luoghi di studio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200025
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
Contatto:
- Yun Feng
- Numero di telefono: +86-17321113771
- Email: fy11697@rjh.com.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.
Descrizione
Inclusion Criteria:
- Age 18 years or older.
- Clinical diagnosis of AHRF and a decision to initiate NIV through an oronasal or full-face mask (PaO2/FiO2 ≤ 300 mmHg or FiO2 ≥ 0.40 to maintain oxygenation target).
- Consent and enrollment completed before NIV begins or within 60 min of initiation.
- Written informed consent from the patient or authorized representative (separate consent for substudy).
Exclusion Criteria:
- Immediate clinical need for endotracheal intubation or clear contraindication to NIV.
- Facial trauma, severe chest-wall skin injury, or incisions preventing safe placement of EIT belt.
- Contraindication in EIT device manual (e.g., incompatible implanted device).
- Pregnancy or lactation.
- Baseline do-not-intubate (DNI) decision or comfort measures only.
- Inability to obtain valid consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Main Cohort
Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). |
|
Nested Physiological Substudy
A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and |Pocc| associations. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)
Lasso di tempo: After 2 hours through 48 hours.
|
The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count) |
After 2 hours through 48 hours.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Discrimination Performance (AUC) of T1 EFI
Lasso di tempo: Within 72 hours
|
Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1) |
Within 72 hours
|
|
Within-Patient Association between EFI and |Pocc|
Lasso di tempo: Within 2 to 6 hours after NIV initiation.
|
The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (|Pocc|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI |
Within 2 to 6 hours after NIV initiation.
|
|
Intubation or Death by Day 7
Lasso di tempo: Within day 7
|
ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants |
Within day 7
|
|
28-Day All-Cause Mortality
Lasso di tempo: within day 28
|
All-cause mortality rate at day 28.Unit of Measure: Proportion of participants |
within day 28
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026846
- (2026) Lin Lun Shen No. 846 (Altro identificatore: Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .